



Express Mail No.: **ED 608 969 344 US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava *et al.*

Confirmation No.: 1802

Application No.: 09/873,403

Art Unit: 1643

Filed: June 4, 2001

Examiner: Christopher H. Yaen

For: COMPLEXES OF ALPHA (2)
MACROGLOBULIN AND ANTIGENIC
MOLECULES FOR IMMUNOTHERAPY

Attorney Docket No: 8449-178-999
(CAM No: 708584-999177)

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.56 AND § 1.97**

MAIL STOP RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the United States Patent and Trademark Office (“USPTO”) of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner’s attention to references **A01-A56, B01-B50, and C08 to C283** listed on the attached form entitled “List of References Cited by Applicant.”

Copies of references **A01, B01-B50** and **C08-C283** are enclosed herewith. Copies of references **A02-A56** are not submitted herewith because they are U.S. patents or U.S. patent application publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as “prior art” against the subject application.

Pursuant to 37 C.F.R. §1.98(a)(3)(i), a concise explanation of the relevance of non-English documents (references B01 and B47) is provided herewith. The relevance of reference B01, German Patent DE 19602985, can be explained by the English translation of

the abstract: Tumor vaccine, for immune therapy of tumors, comprises tumor cells which also contain a gene for an exogenic heat shock protein. The relevance of reference B47, PCT Application No. WO 97/26910, can be explained by the English translation of the abstract:

The invention concerns a tumor vaccine in which the immunogenicity of tumor cells, tumor associated antigens or antigen partial structures are reinforced through genetic modification or through chemical bonding to an exogenous thermal shock protein. The use of microbial thermal shock proteins or their genes is preferred which are derived from mycobacteria, *Escherichia coli* or from *Chlamydia trachomatis*.

While not to be construed as indicating that the Examiner should not review and consider fully all the listed references, Attorneys for Applicant particularly direct the Examiner's attention to references A05, A08, A11, C177-C181, and C184-C186.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97 (b)(4), Applicants believe that no fee is due in connection with the filing of this Supplemental Information Disclosure Statement. However, if the Patent Office determines otherwise, the Commissioner is authorized to charge any required fees to Jones Day deposit account no. 50-3013.

Respectfully submitted,

Date: November 8, 2007


Adriane M. Antler 32,605
(Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
Phone: (212) 326-3939